Analysts expect Dyadic International, Inc. (NASDAQ:DYAI – Get Rating) to report sales of $2.37 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Dyadic International’s earnings. The highest sales estimate is $3.23 million and the lowest is $1.50 million. The business is scheduled to report its next quarterly earnings results after the market closes on Monday, January 1st.
On average, analysts expect that Dyadic International will report full year sales of $11.58 million for the current year, with estimates ranging from $3.90 million to $16.80 million. For the next fiscal year, analysts anticipate that the business will report sales of $19.43 million, with estimates ranging from $4.20 million to $30.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Dyadic International.
Dyadic International (NASDAQ:DYAI – Get Rating) last released its earnings results on Tuesday, March 29th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.11). Dyadic International had a negative return on equity of 58.65% and a negative net margin of 543.68%. The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $5.63 million.
Dyadic International stock opened at $1.95 on Thursday. Dyadic International has a 52-week low of $1.74 and a 52-week high of $6.89. The company has a fifty day simple moving average of $2.80 and a 200-day simple moving average of $3.55.
Several institutional investors and hedge funds have recently made changes to their positions in DYAI. Royal Bank of Canada boosted its stake in Dyadic International by 77.9% during the second quarter. Royal Bank of Canada now owns 6,969 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,051 shares during the period. Teramo Advisors LLC purchased a new position in Dyadic International during the fourth quarter worth about $45,000. Morgan Stanley boosted its stake in Dyadic International by 1,167.3% during the second quarter. Morgan Stanley now owns 13,991 shares of the biotechnology company’s stock worth $51,000 after buying an additional 12,887 shares during the period. Dimensional Fund Advisors LP purchased a new position in Dyadic International during the third quarter worth about $68,000. Finally, Commonwealth Equity Services LLC boosted its stake in Dyadic International by 37.6% during the first quarter. Commonwealth Equity Services LLC now owns 28,018 shares of the biotechnology company’s stock worth $84,000 after buying an additional 7,650 shares during the period. 26.12% of the stock is owned by hedge funds and other institutional investors.
About Dyadic International (Get Rating)
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
- Get a free copy of the StockNews.com research report on Dyadic International (DYAI)
- Wendy’s Growth Story Has Come To An End
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Inflation Hasn’t Peaked At Reynolds Consumer Products
- Is Now The Time To Buy Coinbase (NASDAQ: COIN)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.